INTRODUCTION
7 three or more groups. All statistical analyses were conducted in GraphPad Prism 1 3 7 (GraphPad Software; La Jolla, CA). p<0.05 was considered statistically significant. binding epitopes on the capsid surface. In order to display the ABDCon peptide on VP2 1 4 7 specifically, two separate AAV cap gene variants had to be generated. The first variant, 1 4 8 called pVP2-ABDCon was designed to supply the VP2-ABDCon fusion protein gene. A 1 4 9 second cap gene variant was generated to produce the unmodified VP1 and VP3 1 5 0 capsid proteins (pVP1,3). Altogether, these mutations permit translation of unmodified 1 5 1 AAV9 VP1 and VP3 and the VP2-ABDCon fusion protein to form the AAV9-ABDCon To generate AAV9-ABDCon vector capsids, a modified version of the triple 1 5 6 plasmid transfection method was used where the single rep/cap plasmid is replaced 1 5 7 with the two plasmids encoding for the variant VP1,3, supplying VP1 and VP3, and 1 5 8 VP2-ABDCon, supplying the modified ABDCon-containing VP2, cap genes in a 5:1 ratio 1 5 9 8 (16,17). To assess whether insertion of the ABDCon peptide at the N-terminus of AAV9 1 6 0 VP2 results in the formation of viable vector particles, AAV9 and AAV9-ABDCon vectors 1 6 1 were purified from HEK293 cells 48 h post-transfection and vector titers were 1 6 2 determined by quantitative DNA dot blot. The titers for AAV9-ABDCon were 1 6 3 approximately 70.7% of unmodified AAV9 titers on average (p=0.1875; Figure 2A ). Incorporation of the ABDCon peptide onto the AAV9 VP2 N-terminus was 1 6 5 confirmed by western blot. As expected, the bands corresponding to VP1 (87 kDa) and capsids (73 kDa; Figure 2B ). Vector genome integrity was assessed by alkaline agarose packaged into the AAV9-ABDCon capsids ( Figure 2C ). AAV9-ABDCon binding to HSA was determined by capsid-binding ELISA. Purified vectors were applied to wells on an ELISA plated coated with human serum 1 7 8 albumin. A primary antibody (ADK9) that specifically recognizes intact AAV9 capsids, but not unincorporated AAV capsid VPs, was used to identify samples that were bound background, suggesting that unmodified AAV9 capsid does not bind human serum 1 8 4 albumin with high affinity. In addition, free VP2-ABDCon subunit also did not elicit a 1 8 5 signal, indicating that the ADK9 antibody recognizes intact AAV9 capsids specifically 1 8 6 ( Figure 2D ). HSA-binding AAV9-ABDCon particles were detectable with immuno-TEM 1 8 7 ( Figure 2E ). To assess the impact of ABDCon peptide insertion onto the AAV9 VP2 N-1 9 2 terminus on in vivo transduction and tropism, male and female 6-week old C57BL/6J 1 9 3 mice were injected intravenously with 1x10 13 vg/kg of AAV9 or AAV9-ABDCon vectors was more intense in the livers of male mice treated with the AAV9-ABDCon vector. As female mice across all groups ( Figure 3A) . A higher level of β -gal enzymatic activity was 2 0 0 detected in liver tissue from mice administered the AAV9-ABDCon vector (+319%; 2 0 1 p=0.0008; Figure 3B ). This difference was associated with a higher vector genome copy and AAV9-ABDCon, respectively; p=0.0464; Figure 3C ). was not observed with non-albumin-binding AAV9 vectors containing a VP2 N-terminal 2 1 0 peptide insertion, indicating that the increase in liver transduction was not due to 2 1 1 random peptide insertion at the VP2 N-terminus (data not shown). Altogether, these 2 1 2 results suggest that AAV9-ABDCon achieves increased liver transduction over AAV9, Next, we aimed to evaluate whether the observed increase in liver transduction 2 1 5 by AAV9-ABDCon would translate to a more potent transgene-mediated effect following ligands such as myostatin and the activins (18, 19) . To ensure that the effect would be 2 1 9 limited primarily to Fstn expression and secretion from the liver, we utilized the liver-2 2 0 specific thyroxine-binding globulin (TBG) promoter to drive transgene expression 2 2 1 ( Figure 4A ) (20). 6-week-old male C57BL/6J were injected intravenously with AAV9-2 2 2 TBG-Fstn or AAV9-ABDCon-TBG-Fstn at a dose of 5x10 12 vg/kg or vehicle. As injection (+17.6% and +20.4%; p=0.0053 and p=0.0023 for AAV9 and AAV9-ABDCon, 2 2 6 respectively, relative to vehicle; Figure 4B ). This increase in bodyweight was associated 2 2 7 with skeletal muscle hypertrophy in vector-treated mice, with the largest increase in 2 2 8 11 hindlimb muscle weight measured in mice treated with the AAV9-ABDCon vector 2 2 9 (+19.7%, +17.5% and +16.2%; p=0.0036, p=0.0014 and p=0.0020 for tibialis anterior, Here, we utilize a rational design approach to construct and characterize a HSA improves muscle transduction following intramuscular delivery (10). Although we 2 4 5 do not observe a noticeable improvement in skeletal muscle transduction, we do see in vivo, a finding which has also been reported in studies evaluating the impact of AAV8 2 4 8 pre-incubation in HSA (10,11). However, in contrast to these prior studies, Denard and 2 4 9 colleagues were unable to detect AAV8 binding to HSA, suggesting that a mechanism 2 5 0 other than serum albumin-binding may be responsible (21). Altogether, our results 2 5 1 13 tight binding to serum albumin may impede cellular uptake of the vector, and further 2 7 5 studies will be necessary to determine the impact of reduced binding affinity to serum 2 7 6 albumin on vector transduction. It has been demonstrated that a wide variety of functionalized peptides can be 2 7 8 inserted at the VP2 N-terminus site to impair additional properties to the AAV capsid, 2 7 9 provided the inserted peptide is able to retain its intended conformation (13, 14, 17, 26) .
The addition of a flexible Gly-Ser linker to attach the peptide insert to the AAV capsid 2 8 1 can allow for greater freedom of movement for the conjugated peptide and discourage 2 8 2 steric interference from the capsid (27). From our studies, we find that insertion of a 5.4 2 8 3
kDa ABDCon peptide at the AAV9 VP2 N-terminus appears to result in a small but non-2 8 4 significant decrease in titer when produced in adherent HEK293 cells. There is also 2 8 5 evidence to suggest that VP2 N-terminal insertions may result in an increase in the 2 8 6 empty-to-full capsids ratio (26). These findings indicate that insertions at the AAV VP2 2 8 7 N-terminus may have a mildly detrimental effect on vector production and packaging. As contain a mixed population of both the desired ABDCon-displaying capsids and capsids 2 9 0 containing only VP1 and VP3 (13). This outcome would be expected because it is not 2 9 1 possible to ensure every transfected cell receives a copy of both the pVP1,3 and pVP2- affinity chromatography column (28). We predict a similar chromatographic approach 2 9 7 14 using HSA as the affinity ligand could be used to isolate and purify AAV9-ABDCon 2 9 8 capsids.
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